AI Article Synopsis

  • Ischemic stroke occurs when a blood vessel is blocked, leading to decreased blood flow to the brain, and this study investigates the role of miRNA-143 in this process.
  • The research found that miR-143 is highly present in astrocytes but down-regulated in rat neurons, and its expression increases significantly during ischemic injury, linked to reduced glucose uptake and energy production in the brain.
  • By demonstrating that miR-143 directly targets the glycolysis enzyme HK2, the study suggests that inhibiting miR-143 could protect neurons from ischemic brain injury, pointing to new potential treatments for stroke.

Article Abstract

Ischemic stroke, a major cause of death, is caused by occlusion of a blood vessel, resulting in significant reduction in regional cerebral blood flow. MiRNAs are a family of short noncoding RNAs (18-22 nts) and bind the 3'-UTR of their target genes to suppress the gene expression post-transcriptionally. In the present study, we report that is down-regulated in rat neurones but highly expressed in astrocytes. middle cerebral artery occlusion (MCAO) and oxygen-glucose deprivation (OGD) results showed that miR-143 was significantly induced by ischemia injury. Meanwhile, we observed suppression of glucose uptake and lactate product of rat brain and primary neurones after MCAO or OGD. The glycolysis enzymes hexokinase 2 (HK2), PKM2, and LDHA were inhibited by MCAO or OGD at protein and mRNA levels. In addition, overexpression of miR-143 significantly inhibited HK2 expression, glucose uptake, and lactate product. We report that HK2 is a direct target of miR-143. Importantly, restoration of HK2 in miR-143 overexpressing rat neurones recovered glucose uptake and lactate product. Our results demonstrated inhibition of miR-143 during OGD could protect rat neuronal cells from ischemic brain injury (IBI). In summary, the present study reveals a miRNA-mediated neuron protection during IBI, providing a new strategy for the development of therapeutic agents against IBI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434090PMC
http://dx.doi.org/10.1042/BSR20170216DOI Listing

Publication Analysis

Top Keywords

glucose uptake
16
uptake lactate
12
lactate product
12
rat neurones
8
mcao ogd
8
mir-143
5
inhibition ischemia
4
ischemia cerebral
4
cerebral injury
4
injury protects
4

Similar Publications

Background: Cerebral blood flow (CBF) and glucose utilization have both proven sensitive biomarkers of brain function in Alzheimer's disease. However, while blood flow supplies glucose to cells to meet local demand, and therefore, are inter-related, the two aspects are physiologically distinct. Our goal was to conduct a region-to-region correlation of magnetic resonance imaging (MRI) and F-fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers of cerebral blood flow and glucose utilization to determine whether these physiologically distinct biomarkers yield functionally distinct information.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Imperial College London, London, UK.

Background: Alzheimer's disease and type 2 diabetes mellitus rank among the top ten leading global causes of death. The association between diabetes and Alzheimer's is linked to chronic low-grade inflammation, hyperinsulinemia, and the interplay between peripheral and central insulin resistance, influencing insulin signalling. We evaluated the association between diabetes and Alzheimer's-related neuropathology in cognitively unimpaired older adults with diabetes.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Vaccinex, Inc., Rochester, NY, USA.

Background: The earliest recognized biomarker of AD is deposition of Aβ amyloid that leads to formation of plaques and may, over time, trigger or at least be followed by gliosis/neuroinflammation and neurofibrillary tangles, accompanied by neurodegenerative changes including neuronal and synaptic loss. We have previously reported that semaphorin 4D (SEMA4D), the major ligand of plexin B receptors expressed on astrocytes, is upregulated in diseased neurons during progression of AD and Huntington's disease (HD). Binding of SEMA4D to PLXNB receptors triggers astrocyte reactivity, leading to loss of neuroprotective homeostatic functions, including downregulation of glutamate and glucose transporters (doi:10.

View Article and Find Full Text PDF

Background: Insulin resistance (IR) is associated with abnormal tau-phosphorylation and IR markers in AD brain co-localize with neurofibrillary tangles. One strategy to overcome brain IR is to increase brain insulin is via intranasal insulin (INI) administration using specialized intranasal devices that deliver insulin to the brain. Our recent INI vs.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is the most common form of dementia, predominantly manifesting as amnestic impairment. However, atypical presentations such as logopenic variant of primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), corticobasal syndrome (CBS) and frontal AD pose diagnostic challenges. This study presents preliminary data from a retrospective analysis investigating brain functional differences between typical and atypical AD forms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!